1.86
Lexicon Pharmaceuticals Inc (LXRX) 最新ニュース
Lexicon Pharmaceuticals Q2 2025 Earnings Preview - MSN
Growth Report: What is the target price for Lexicon Pharmaceuticals Inc stock2026 Update & Weekly High Return Opportunities - baoquankhu1.vn
IPO Launch: Is Lexicon Pharmaceuticals Inc stock trending bullish2026 Key Lessons & Intraday High Probability Alerts - baoquankhu1.vn
LXRX SEC FilingsLexicon Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
LXRX stock up as NVO initiates phase I study of partnered obesity drug - MSN
Buyback Watch: Can Lexicon Pharmaceuticals Inc reach all time highs this year2026 Recap & Real-Time Volume Spike Alerts - baoquankhu1.vn
Lexicon Pharmaceuticals, Inc. (LXRX) stock price, news, quote and history - Yahoo Finance UK
Lexicon Pharmaceuticals (LXRX) price target increased by 15.07% to 3.43 - MSN
How The Lexicon Pharmaceuticals (LXRX) Story Is Shifting Around Pilavapadin And Valuation Assumptions - Yahoo Finance
LXRX Technical Analysis & Stock Price Forecast - Intellectia AI
Lexicon Pharmaceuticals, Inc. (LX31.MU) stock price, news, quote and history - Yahoo Finance UK
Lexicon Pharmaceuticals joins Texas Life Sciences Summit to engage industry leaders and drive sector momentum - Traders Union
LXRX Stock Chart | LEXICON PHARMACEUTICALS INC (NASDAQ:LXRX) - ChartMill
Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading 8.7% HigherTime to Buy? - MarketBeat
Certain Stock Options of Lexicon Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 1-APR-2026. - marketscreener.com
Certain Restricted Stock Units of Lexicon Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 1-APR-2026. - marketscreener.com
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Passes Above Two Hundred Day Moving AverageHere's Why - MarketBeat
Lexicon Pharmaceuticals unveils ACC26 trial analysis on BMI and cardiovascular outcomes - Traders Union
Published on: 2026-03-29 16:03:42 - baoquankhu1.vn
Lexicon Pharmaceuticals unveils new SOTA‑P‑CARDIA Chapter 2 data in HFpEF at ACC26 - Traders Union
Lexicon Pharmaceuticals Stock: Pipeline Progress and Financial Strategy in Biopharma Sector - AD HOC NEWS
ACC meeting features Lexicon Pharmaceuticals clinical research presentations - Traders Union
LXRX Stock Up as NVO Initiates Phase I Study of Partnered Obesity Drug - Yahoo Finance
Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo - Bitget
Lexicon brings ACC data showing heart benefits across BMI groups - Stock Titan
Lexicon Pharmaceuticals (LXRX) Receives Reiterated Buy Rating at $6.00 | LXRX Stock News - GuruFocus
Lexicon Pharmaceuticals' (LXRX) Buy Rating Reaffirmed at HC Wainwright - marketbeat.com
Novo Nordisk Begins Study of Lexicon Oral Obesity Drug - wsj.com
Lexicon Pharmaceuticals And Novo Nordisk Announce Initiation Of Phase 1 Study With Oral Obesity Drug Candidate LX9851 - TradingView
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851 - Yahoo Finance
HC Wainwright remains a buy on Lexicon Pharmaceuticals (LXRX) - MSN
Published on: 2026-03-22 17:56:17 - baoquankhu1.vn
LXRX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
H.C. Wainwright Remains a Buy on Lexicon Pharmaceuticals (LXRX) - Insider Monkey
Lexicon Pharmaceuticals advances chronic pain treatment options with focus on non opioid innovation - Traders Union
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2025 Earnings Call Transcript - MSN
Lexicon Pharma spikes after insider buy - MSN
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Crosses Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Growth Value: How does Lexicon Pharmaceuticals Inc compare to its peers2026 EndofMonth & Low Drawdown Investment Ideas - baoquankhu1.vn
Dip Buying: How much upside does Lexicon Pharmaceuticals Inc have2026 PreEarnings & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
HC Wainwright raises its price target on Lexicon Pharmaceuticals, Inc. (LXRX) to $6 from $4 and maintains a buy rating - MSN
Lexicon Pharmaceuticals, Inc.Common Stock (NQ: LXRX - The Chronicle-Journal
Lexicon Pharmaceuticals (LXRX) 2025 10-K: pipeline updates, collaborations - Stock Titan
大文字化:
|
ボリューム (24 時間):